Lv2
200 积分 2022-05-11 加入
The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies
5小时前
已完结
Resistance to EGFR Inhibitors: Fitness, Competition, and Diversity
7个月前
已完结
Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis
7个月前
已完结
Carboxylesterase inhibitors from clinically available medicines and their impact on drug metabolism
8个月前
已完结
BAY 2927088: The first non-covalent, potent, and selective tyrosine kinase inhibitor targeting EGFR exon 20 insertions and C797S resistance mutations in NSCLC
8个月前
已完结
[Chinese expert consensus on the multidisciplinary clinical diagnosis and treatment of stage Ⅲ non-small cell lung cancer (2019)]
8个月前
已完结
Cancer incidence and mortality in China, 2022
9个月前
已完结
Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
9个月前
已完结
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
9个月前
已完结
Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine
9个月前
已完结
皖公网安备34019202002308
